- **Press Release** -

LFB'S RAISON D'ÊTRE GUIDES AN AMBITIOUS CSR STRATEGY

***Les Ulis (France) – 12 November 2025* – As a major player in the production of plasma-derived biopharmaceuticals and recombinant proteins, LFB now presents its new corporate social responsibility (CSR) strategy, which is centred on patients and guided by the company's raison d'être "LFB, expertise committed to life". This core principle underscores the Group's conviction that acting for health is acting for society and the planet as a whole.**

A unique company in the healthcare landscape

For more than thirty years, LFB has been manufacturing in France life-saving medicines from human plasma for the treatment of serious and rare diseases. LFB is a healthcare company like no other, with a public health mission that puts people at the heart of its performance and innovation.

True to this mission, the Group is now implementing a structured CSR strategy that links social responsibility, environmental sustainability and scientific performance in service of patients.

"Our raison d'être, our purpose, takes on its full meaning with the roll-out of this CSR strategy. It reflects our concrete commitment to the health of patients and the protection of the environment, while also increasing our positive impact on our employees, and society. Being a responsible healthcare player also means thinking long-term, for the good of future generations", says **Jacques Brom, CEO of LFB**.

A collective, measurable approach

The strategy was built in a participatory manner and draws on the energy of LFB as a whole. An Operational CSR Committee chaired by Jacques Brom is responsible for monitoring the deployment of the strategy, coordinating around twenty cross-cutting programmes and monitoring the progress of specific social and environmental performance indicators.

In addition to the quantifiable objectives, LFB's approach embodies a collective movement: that of a healthcare company that wants to make responsibility a force for sustainable transformation, all in the service of patients, employees, and future generations.

Four pillars for a sustainable transformation

LFB's CSR strategy is structured around four commitment pillars, each of which reflect its vision of a healthcare company resolutely focused on the future.

1. Serving patients: ensuring access to life-saving treatments

Every day, more than 300,000[1] patients in Europe depend on plasma-derived medicinal products. The unique responsibility to meet this demand has led the Group to commit to triple its production capacity in the long term, including via a new production site in Arras, and to double its number of production sites approved by international health authorities by 2030.

From 2026 onwards, 100% of strategic product development projects will be presented to the relevant patient associations in order to address their expectations from the design stage. This participatory approach illustrates LFB's desire to make sure its model fits as closely as possible with the real needs of patients.

---

[1] *PPTA, 2021*. Source: https://cdn.prod.website-files.com

2. Respecting the environment: making health sustainable

Human health and the environment are inextricably linked. For LFB, reducing its environmental footprint is key to its transformation. The company aims to reduce its greenhouse gas emissions by 43% (scopes 1, 2, and 3, compared with 2022) and its water consumption by 10% by 2030. It has also set its sights on completing a carbon footprint assessment of products representing 80% of its revenue from sales by 2030. These environmental targets have also been paired with industrial innovations: process optimisations, responsible waste management, and more sustainable packaging.

3. Committing to our teams: protecting and developing talent

The women and men of LFB are the key to its excellence. The Group strives to foster a safe, inclusive, and meaningful environment in which each and every employee can thrive. As a result, its goal has been to reduce by 80% work-related accidents with work interruption, and to raise awareness among 100% of its employees to CSR issues, by 2030.

LFB also works to strengthen its continuing education and skills development programmes so that all employees have a development and expertise plan by 2030. LFB continues to promote internal mobility, with more than 20% of its employees change positions each year. The Group views diversity and professional equality as a lever for innovation and collective performance, through a healthy mix of generations, a diversity of profiles, and a robust mentoring system.

4. Acting with integrity: building trust at every step

All of LFB's decisions are guided by ethics, transparency, and responsibility. The Group aims to train 100% of its employees on its Code of Conduct by 2028 and to prioritise collaborations with partners aligned with its CSR values. LFB also wants to ensure that 90% of active donors in its collection centres rate their donation experience as good or excellent by 2030.

About LFB

LFB is a bio-pharmaceutical group that develops, manufactures, and markets plasma-derived medicinal products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European suppliers of plasma-derived medicinal products to healthcare professionals. Its vision is to provide patients with new treatment options in three major therapeutic areas: immunology, haemostasis, and intensive care. LFB currently markets 15 medicinal products in more than 30 countries. For more information about LFB, go to www.groupe-lfb.com.

LFB Press Contact: Havas Paris - Noa Romero

Phone: +33 6 42 04 95 74 – E-mail noa.romero@havas.com